06.09.2011 – 12:33
Indivumed appoints Dr. Helge Bastian as Managing Director and Chief Commercial Officer
Indivumed is pleased to announce that Helge Bastian, Ph.D, will join Indivumed as Managing Director and Chief Commercial Officer on September 12, 2011.
Hartmut Juhl, founder and CEO of Indivumed, says: "The board and me personally are proud to have Dr. Bastian with Indivumed today. His tremendous background, global expertise and leadership experience will support the further development of our company."
Dr. Bastian has over 19 years of international leadership experience in corporations serving the molecular biology, life science research, diagnostics, biotechnology, drug development and pharmaceutical manufacturing industry. Previously, Dr. Bastian was Vice President of Global Marketing, Business Development & Strategy for the Research Biotech business unit and member of the leadership team at Sigma-Aldrich in St. Louis, USA.
He worked as Executive Vice President of Life Science Services business unit and member of Senior Executive Management Team at SGS in Geneva, Switzerland. Dr. Bastian joined SGS after more than eleven years with QIAGEN in Duesseldorf, Germany, where he held various management positions, most recently as Vice President Molecular Diagnostics, Vice President Global Strategic Marketing, Vice President PreAnalytix and member of executive steering committee.
Dr. Bastian holds a diploma in biology (focus area of biochemistry) and a Ph.D. in molecular biology. He is an alumnus from the Max- Planck-Network and the Columbia Business School. "Quickly translating new molecular discoveries into medical practice to improve the diagnosis and treatment of diseases that are life- threatening, such as cancer, is an absolute necessity and addresses a genuine demand," Dr. Bastian explains his decision to join Indivumed. "As a strong believer in personalized medicine approaches, I am extremely intrigued by Indivumed's approach to improve cancer research and drug development, and I am excited about having the opportunity to further expand the Indivumed product and service portfolio."
Indivumed GmbH was founded in 2002 and maintains the world's leading tumor database and high-quality biobank for the development of new cancer diagnostics and therapies. The biotechnology company provides a unique research infrastructure through collaboration with clinics, oncology networks and special technologies and is recognized by numerous pharmaceutical companies and leading academic institutions as a quality-focused research partner and service provider. With an extraordinary collection of biological samples taken from more than 13,000 cancer patients, Indivumed provides research services such as immunohistochemical screening, profiling of new anti-cancer agents on viable primary tumor tissues, a wide range of biospecimen formats taken from Indivumed's own biobank and other research services with a focus on analyzing pathways relevant to cancer and new targeted therapeutics.
In 2008, Indivumed, together with scientists from the John Hopkins University in Baltimore, founded Inostics GmbH, a biotech company that specializes in DNA diagnostics. Indivumed has its main office in Hamburg and a subsidiary, Indivumed Inc., in Kensington, Maryland, USA. For more information, please visit www.indivumed.com .
Original content of: Indivumed GmbH, transmitted by news aktuell